C Bokemeyer

Summary

Affiliation: University of Hamburg
Country: Germany

Publications

  1. doi request reprint A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer
    Carsten Bokemeyer
    Department of Internal Medicine II Hematology, Oncology, Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Gastric Cancer 18:833-42. 2015
  2. pmc Micro-RNA expression in cisplatin resistant germ cell tumor cell lines
    Matthias Port
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Mol Cancer 10:52. 2011
  3. pmc Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
    Leticia Oliveira-Ferrer
    Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Exp Clin Cancer Res 27:86. 2008
  4. pmc Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Jan K Hennigs
    Centre for Pulmonary Hypertension, University Medical Centre Hamburg Eppendorf, 20246 Hamburg, Germany
    BMC Pulm Med 11:30. 2011
  5. pmc Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
  6. ncbi request reprint Anaemia in cancer patients: pathophysiology, incidence and treatment
    C Bokemeyer
    Department of Oncology, Haematology, Bone Marrow, Transplantation and Pneumology, University of Eppendorf Medical Center, Hamburg, Germany
    Eur J Clin Invest 35:26-31. 2005
  7. doi request reprint Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
  8. ncbi request reprint EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
    C Bokemeyer
    Universitaetsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany, and Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Cancer 43:258-70. 2007
  9. doi request reprint Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites
    Carsten Bokemeyer
    Universitatsklinikum Hamburg Eppendorf, Department of Oncology, Hematology, BMT With Section Pneumology, Hamburg, Germany
    Expert Opin Biol Ther 10:1259-69. 2010
  10. doi request reprint Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    C Bokemeyer
    Department of Oncology, Hematology, BMT With Section Pneumology, University Hospital, Hamburg Eppendorf, Germany
    Ann Oncol 22:1535-46. 2011

Collaborators

Detail Information

Publications97

  1. doi request reprint A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer
    Carsten Bokemeyer
    Department of Internal Medicine II Hematology, Oncology, Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Gastric Cancer 18:833-42. 2015
    ..Perioperative administration of catumaxomab could potentially eliminate residual tumour cells after intended curative resection of the primary tumour...
  2. pmc Micro-RNA expression in cisplatin resistant germ cell tumor cell lines
    Matthias Port
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Mol Cancer 10:52. 2011
    ..We compared microRNA expression patterns in three cisplatin resistant sublines derived from paternal cisplatin sensitive germ cell tumor cell lines in order to improve our understanding of the mechanisms of cisplatin resistance...
  3. pmc Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
    Leticia Oliveira-Ferrer
    Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Exp Clin Cancer Res 27:86. 2008
    ..Aim of the current study was to investigate effects of cilengitide on endothelial and glioma cells on molecular and cellular levels...
  4. pmc Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Jan K Hennigs
    Centre for Pulmonary Hypertension, University Medical Centre Hamburg Eppendorf, 20246 Hamburg, Germany
    BMC Pulm Med 11:30. 2011
    ..Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib...
  5. pmc Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
    ..In the European Union and United States, ESA therapy initiation for CIA is now recommended at a Hb level < or = 10 g/dL. The present exploratory analysis examined how ESA initiation at this Hb level may impact patient care...
  6. ncbi request reprint Anaemia in cancer patients: pathophysiology, incidence and treatment
    C Bokemeyer
    Department of Oncology, Haematology, Bone Marrow, Transplantation and Pneumology, University of Eppendorf Medical Center, Hamburg, Germany
    Eur J Clin Invest 35:26-31. 2005
    ..Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients' situation...
  7. doi request reprint Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
    ..The influence of KRAS mutation status was investigated...
  8. ncbi request reprint EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
    C Bokemeyer
    Universitaetsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany, and Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Cancer 43:258-70. 2007
    ..While our review did not address cost benefit evaluations in detail, the consensus is that studies taking into account all real determinants of cost and benefit need to be performed prospectively...
  9. doi request reprint Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites
    Carsten Bokemeyer
    Universitatsklinikum Hamburg Eppendorf, Department of Oncology, Hematology, BMT With Section Pneumology, Hamburg, Germany
    Expert Opin Biol Ther 10:1259-69. 2010
    ..The European Medicines Agency (EMA) approved the use of a trifunctional bispecific antibody, catumaxomab (Removab), for the intraperitoneal (i.p.) treatment of malignant ascites in April 2009...
  10. doi request reprint Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    C Bokemeyer
    Department of Oncology, Hematology, BMT With Section Pneumology, University Hospital, Hamburg Eppendorf, Germany
    Ann Oncol 22:1535-46. 2011
    ....
  11. ncbi request reprint Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer
    J Wierecky
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, University of Tuebingen Medical Center, Otfried Mueller Strasse 10, 72076 Tuebingen, Germany
    J Cancer Res Clin Oncol 131:255-60. 2005
    ..We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer...
  12. ncbi request reprint Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group
    C Bokemeyer
    Department of Oncology Hematology, University Medical Centre Eppendorf, Hamburg, Germany
    Ann Oncol 19:448-53. 2008
    ..The aim of this study is to determine feasibility and efficacy of the combination regimen gemcitabine, oxaliplatin, and paclitaxel (GOP) in patients with cisplatin-refractory or multiply relapsed germ-cell tumors...
  13. doi request reprint Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy
    K Oechsle
    Department of Oncology, University Medical Center Eppendorf, Hamburg, Germany
    Eur J Cancer 44:1663-9. 2008
    ..Retrospective analysis of characteristics and outcome of germ cell tumour (GCT) patients with cerebral metastases (CM) undergoing high-dose chemotherapy (HD-CTX) or relapsing with CM...
  14. ncbi request reprint Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide
    J T Hartmann
    Department of Hematology, Oncology, Immunology, UKT Medical Center II, University of Tubingen, Germany
    Anticancer Res 20:3767-73. 2000
    ..In the light of the long-term consequences of persistent renal damage prevention of nephrotoxicity should be further improved...
  15. doi request reprint Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
    K Oechsle
    Division of Oncology, Hematology, Bone Marrow Transplantation and Section Pneumology, University Medical Centre Eppendorf, Hamburg University, Germany
    Ann Oncol 22:2654-60. 2011
    ..The objective of the study was to investigate the activity of sunitinib in a cell line model and subsequently in patients with cisplatin-refractory or multiply relapsed germ cell tumors (GCT)...
  16. ncbi request reprint Patterns of relapse after primary or salvage high-dose chemotherapy in patients with advanced nonseminomatous germ cell tumors
    K Oechsle
    University Hospital Hamburg Eppendorf, Hamburg, Germany University Hospital Giessen und Marburg GmbH, Marburg, Germany British Columbia Cancer Agency, Vancouver Cancer Center, Vancouver, BC, Canada University of Tübingen Medical Center, Tuebingen, Germany Vivantes Klinikum Am Urban, Berlin, Germany
    J Clin Oncol 26:16012. 2008
    ..We retrospectively analysed the pattern of relapse after primary or salvage high dose chemotherapy (HD-CTX) to critically evaluate common follow-up procedures...
  17. doi request reprint Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
    G Schilling
    Onkologisches Zentrum, II Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg Eppendorf, Martinistr 52, 20246, Hamburg, Germany
    Invest New Drugs 27:166-72. 2009
    ..This phase II trial of vinorelbine and trastuzumab demonstrated an effective and well-tolerated regimen with a favourable safety profile...
  18. doi request reprint Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update
    D Koychev
    Universitatsklinikum Hamburg Eppendorf, Hubertus Wald Tumorcenter, Oncology, Haematology and Bone Marrow Transplantation with Section Pulmology, Hamburg, Germany
    Int J Androl 34:e266-73. 2011
    ..Currently, a number of mechanisms of cisplatin resistance and potential drug targets like global methylation and BRAF mutation status are under investigation in refractory GCT...
  19. doi request reprint Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients
    S Kobold
    1 Department of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, Department of Internal Medicine II, University Cancer Center Hamburg Hubertus Wald Tumorzentrum, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 46:1053-6. 2011
    ..Accordingly, plerixafor seems to be safe and effective in germ cell tumor patients who have failed prior mobilization therapy. Larger prospective studies are warranted to further assess its use in germ cell cancer...
  20. ncbi request reprint Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab
    S Tejpar
    University Hospital Gasthuisberg, Leuven, Belgium University Medical Center Hamburg Eppendorf, Hamburg, Germany Merck KGaA, Darmstadt, Germany
    J Clin Oncol 29:3511. 2011
    ..We investigated the influence of the KRAS codon 13 mutation G13D on clinical outcome compared with pts with other KRAS tumor mutations or KRAS wt tumors in a pooled analysis of pts from the CRYSTAL and OPUS studies...
  21. ncbi request reprint Chemokine CXCL13 is overexpressed in the tumor tissue and in the peripheral blood of breast cancer patients
    D Atanackovic
    University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 26:22029. 2008
    ..However, little is known about the relation between chemokine expression and the development and progression of solid tumors like breast cancer...
  22. ncbi request reprint High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ cell tumors
    J Beyer
    Vivantes Klinikum Am Urban, Berlin, Germany University Hospital Giessen Marburg, Marburg, Germany Charité, Campus Mitte, Berlin, Germany Klinikum Reinhardshöhe, Bad Wildungen, Germany University Hospital Tuebingen, Tuebingen, Germany University Hospital Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 27:5082. 2009
    ..5082 Background: To determine the activity of high-dose chemotherapy (HDCT) as intensification of second salvage treatment (SST) in patients with multiple relapsed germ-cell tumors (GCT)...
  23. ncbi request reprint Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: Lessons from the OPUS trial
    H Piessevaux
    Cliniques Universitaires Saint Luc, Universitá Catholique de Louvain, Brussels, Belgium Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany Global Biostatistics, Global Clinical Operations, Merck KGaA, Darmstadt, Germany Global Clinical Development Unit, Oncology, Merck KGaA, Darmstadt, Germany Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 29:398. 2011
    ..This was investigated in pts treated with the FOLFOX4 regimen ± cet in the OPUS trial...
  24. ncbi request reprint An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    J T Hartmann
    Department of Medical Oncology, Hematology, Immunology, Rheumatology, Pneumology, South West German Cancer Center, Eberhard Karls University, Tuebingen, Germany
    Invest New Drugs 24:249-53. 2006
    ..The aim of this trial was to evaluate the efficacy of gemcitabine in this setting...
  25. ncbi request reprint Relevant bleeding diathesis due to acquired factor XIII deficiency
    M Janning
    Priv Doz Dr med Florian Langer, II Medizinische Klinik und Poliklinik, Hubertus Wald Tumorzentrum Universitäres Cancer Center Hamburg UCCH, Universitätsklinikum Eppendorf, Martinistr 52, 20246 Hamburg, Germany, Tel 49 0 40 741 05 24 53, Fax 49 0 40 741 05 51 93, E mail
    Hamostaseologie 33:S50-4. 2013
    ..In contrast, only limited information is available on the haemostatic relevance of acquired FXIII deficiency in non-surgical patients...
  26. pmc Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
    C Seidel
    Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Eppendorf, Martinistrase 52, 20246 Hamburg, Germany
    Br J Cancer 109:2998-3004. 2013
    ..The aim of our analysis is to further characterise the prognostic relevance of early tumour shrinkage (TS) during VEGF-targeted therapy in mRCC, in order to explore whether this could define a group of patients with long-term survivorship...
  27. doi request reprint HER-2/neu analysis in breast cancer bone metastases
    J Zustin
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Pathol 62:542-6. 2009
    ..HER-2 can be analysed by fluorescence in situ hybridisation (FISH) for gene amplification or immunohistochemistry (IHC) for protein overexpression...
  28. ncbi request reprint [Haemostatic aspects in clinical oncology]
    F Langer
    Onkologisches Zentrum, II Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg
    Hamostaseologie 28:472-80. 2008
    ....
  29. doi request reprint The impact of social factors on outcomes in patients with bleeding disorders
    K Holstein
    II Medical Department, Haemophilia Centre, University Medical Centre, Hamburg, Germany
    Haemophilia 22:46-53. 2016
    ..Information about the relevance of patient-related factors such as education, social status or impact of the disease on the patient's life is scarce...
  30. doi request reprint Expression and release of platelet protein disulphide isomerase in patients with haemophilia A
    M Voigtlaender
    II Medizinische Klinik und Poliklinik, Hubertus Wald Tumorzentrum Universitäres Cancer Center Hamburg UCCH, Universitätsklinikum Eppendorf, Hamburg, Germany
    Haemophilia 22:e537-e544. 2016
    ..Protein disulphide isomerase (PDI) is an abundant oxidoreductase that exerts pleiotropic effects in primary and secondary haemostasis and contributes to thrombosis and vascular inflammation...
  31. ncbi request reprint Outcome according to metastatic site in patients with KRAS wild-type tumors: Analysis from the CRYSTAL and OPUS studies
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany Global Clinical Development Unit, Oncology, Merck KGaA, Darmstadt, Germany European Hospital George Pompidou, Paris, France Onkologie Klinikum Oldenburg, Oldenburg, Germany
    J Clin Oncol 29:472. 2011
    ..R0 resection of colorectal liver metastases is a potentially curative option in this setting. In this descriptive analysis of these trials the benefit of adding cet to CT according to metastatic site was investigated...
  32. doi request reprint Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
    G Schilling
    Department of Oncology and Hematology, Medical Clinic II, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 22:1250-5. 2008
    ..Translocation t(4;14) might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies...
  33. pmc Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
    S Koch
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, , , Tuebingen 72076, Germany
    Br J Cancer 89:2133-9. 2003
    ....
  34. pmc Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients
    J Panse
    Department of Oncology Hematology, Center of Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg 20246, Germany
    Br J Cancer 99:930-8. 2008
    ....
  35. ncbi request reprint Experimental metastasis and primary tumor growth in mice with hemophilia A
    F Langer
    II Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    J Thromb Haemost 4:1056-62. 2006
    ..Although TF expression by B16F10 cells may promote thrombin-dependent metastasis in mice with hemophilia A, amplification of coagulation by host FVIII appears to be necessary for maximum lung seeding...
  36. doi request reprint [A multi-disciplinary approach to the treatment of germ cell tumors]
    F Honecker
    Onkologisches Zentrum, II Medizinische Klinik und Poliklinik, Hubertus Wald Tumorzentrum, Universitäres Cancer Center Hamburg UCCH, Universitatsklinikum Hamburg Eppendorf, Martinistrase 52, 20246, Hamburg
    Internist (Berl) 51:1382-7. 2010
    ..Complex cases with poor prognosis and all patients with relapsed disease should exclusively be treated by experts in a tertiary care setting to achieve highest possible cure rates in these young patients...
  37. doi request reprint Gene amplification in ductal carcinoma in situ of the breast
    L Burkhardt
    Department of Pathology, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246, Hamburg, Germany
    Breast Cancer Res Treat 123:757-65. 2010
    ..Therefore, our data suggest an early role of all analyzed gene amplifications in breast cancer development but not in the initiation of invasive tumor growth...
  38. ncbi request reprint Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer
    I Thoem
    University Hospital Hamburg Eppendorf, Hamburg, Germany Herlev Hospital, University of Copenhagen, Copenhagen, Denmark German Cancer Research Center, Heidelberg, Germany
    J Clin Oncol 26:19044. 2008
    ..The purpose of this study was to evaluate YKL-40 in pretreatment serum samples from patients with metastatic NSCLC...
  39. ncbi request reprint Results from the pilot phase of the IN-GHO registry for elderly cancer patients
    F U Honecker
    University Medical Center, Hamburg, Germany University Medical Center, Jena, Germany Ortho Biotech, Division of Janssen Cilag GmbH, Neuss, Germany
    J Clin Oncol 26:20654. 2008
    ..In order to gain more insight into feasibility of cancer treatment, results of a short geriatric assessment (GA), physicians' and pts' judgement of fitness, and outcome measures were studied...
  40. ncbi request reprint Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report
    G Schilling
    University Hospital Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 27:e21527. 2009
    ..Systemic therapy, however, is not standardized. Small cohorts have been treated with interferon, chemotherapy and angiogenesis inhibitors such as thalidomide with various results...
  41. ncbi request reprint Use of the Comprehensive Geriatric Assessment (CGA) in elderly patients (pts) with solid tumors to predict mortality
    F U Honecker
    Oncology Center, Hamburg, Germany Jena University Hospital, Jena, Germany Gesellschaft fuer Evaluation und Qualitaetssicher, Meerbusch, Germany Ortho Biotech, Division of Janssen Cilag GmbH, Neuss, Germany
    J Clin Oncol 27:9549. 2009
    ..We report data from 1130 pts with solid tumors. Results of a CGA, physicians' and pts' judgement of fitness were studied in relation to mortality within 5-7 months...
  42. ncbi request reprint Diagnosis, treatment, and use of intravenous iron for chemotherapy-induced anemia in Europe
    M S Aapro
    Clinique de Genolier, Genolier, Switzerland University Hospital Liege, Liege, Belgium University Medical Center Hamburg Eppendorf, Hamburg, Germany David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA Sundsvall Hospital, Sundsvall, Sweden John Radcliffe Hospital, Oxford, United Kingdom Wilhelminenspital der Stadt Wien, Vienna, Austria Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden Vifor Pharma, Glattbrugg, Switzerland
    J Clin Oncol 29:e19557. 2011
    ..Intravenous (I.V.) iron in conjunction with an erythropoiesis-stimulating agent (ESA) is a well tolerated and effective therapy. This study evaluated current practice in diagnosis and treatment of CIA in nine European countries...
  43. ncbi request reprint Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial
    A Lorch
    University Hospital Marburg, Marburg, Germany Unite de Methodologie et Biostatistique, Centre Oscar Lambret, Lille, France Kiel University Hospital, Kiel, Germany University Medical Center Hamburg Eppendorf, Hamburg, Germany Klinik Reinhardshöhe GmbH, Bad Wildungen, Germany Vivantes Klinikum Am Urban, Berlin, Germany
    J Clin Oncol 29:4507. 2011
    ..4507 Background: Sequential and single high-dose chemotherapy (HDCT) can both be curative in patients (pts) with relapsed or refractory germ-cell tumors (GCT). The long-term efficacy of either modality is unknown...
  44. doi request reprint Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor
    K Holstein
    Dr Katharina Holstein, II Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Martinistr 52, 20246 Hamburg, Germany, Tel 49 0 40 741 05 24 53, Fax 5193, E mail
    Hamostaseologie 34:S5-8. 2014
    ..No allergic reactions, nephrotic syndrome or serious infection occurred during ITI. The FIX inhibitor was undetectable after five weeks of treatment and remained so until 19 months of follow-up. ..
  45. ncbi request reprint Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone
    K Holstein
    II Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    Hamostaseologie 32:S48-51. 2012
    ..Development of FVIII inhibitors represents a major challenge in patients with mild haemophilia A (HA), because they tend to occur at an older age and classical immune tolerance induction appears to be less effective...
  46. doi request reprint Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor
    F Langer
    Hubertus Wald Tumorzentrum Universitäres Cancer Center Hamburg, Universitatsklinikum Hamburg Eppendorf, Hamburg
    Hamostaseologie 32:95-104. 2012
    ....
  47. doi request reprint Phase I trial of SU14813 in patients with advanced solid malignancies
    W Fiedler
    Department of Oncology, Hematology, BMT With Section Pneumology, Hubertus Wald Tumorzentrum, University Cancer Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Oncol 22:195-201. 2011
    ..this phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors...
  48. ncbi request reprint Antiangiogenic treatment with endostatin inhibits progression of AML in vivo
    G Schuch
    Department of Medicine, Oncology and Hematology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 19:1312-7. 2005
    ..Taken together, ES has inhibitory effects on neo-angiogenesis in the bone marrow and on progression of leukemia in vivo. These experiments suggest a possible therapeutic role of antiangiogenic gene therapy with ES in AML...
  49. pmc Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report
    G B Iwanski
    Department of Internal Medicine, Oncology and Hematology, University Hospital Hamburg, Eppendorf, Martinistrasse, Hamburg, Germany
    J Med Case Rep 2:115. 2008
    ..The incidence of esophageal cancer varies greatly among regions of the world and occurs at a high frequency in Asia and South America...
  50. doi request reprint Detrimental social interactions predict loss of dignity among patients with cancer
    R Philipp
    Department of Medical Psychology, University Medical Center Hamburg Eppendorf, Martinistr 52 W26, 20246, Hamburg, Germany
    Support Care Cancer 24:2751-8. 2016
    ....
  51. pmc Improved nutrition in adolescents and young adults after childhood cancer - INAYA study
    J Quidde
    Department of Oncology, Hematology, BMT With Section Pneumology, Hubertus Wald Tumour Center University Cancer Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246, Hamburg, Germany
    BMC Cancer 16:872. 2016
    ..Compared to the general population AYAs have a 5 to 15-fold increased risk of cardiovascular morbidity. Thus, improving modifiable lifestyle risk factors is of particular importance...
  52. ncbi request reprint Effects of aerobic exercise training on physical performance during myeloablative therapy
    M de Wit
    Vivantes Klinikum Neukölln, Berlin, Germany University Clinic Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 26:9502. 2008
    ....
  53. ncbi request reprint Impact of Primary Metastatic Bone Disease in Germ Cell Tumors: Results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study
    C Oing
    Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Eppendorf, Hamburg, Germany
    Ann Oncol . 2016
    ..Bone metastases (BM) are rare in germ cell tumor (GCT) patients. Systematic data on risk factors, treatment and outcome are largely lacking...
  54. ncbi request reprint Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies
    H Piessevaux
    Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium University Hospital Gasthuisberg, Leuven, Belgium University Medical Center Hamburg Eppendorf, Hamburg, Germany Merck KGaA, Darmstadt, Germany
    J Clin Oncol 29:3572. 2011
    ..We used the CRYSTAL and OPUS studies to quantify the predictive power of tumor size changes at week (wk) 8 for long-term outcome investigating heterogeneity across treatment arms (CT or CT + cet)...
  55. ncbi request reprint Incorporation of geriatric assessment into oncology practive: Views and attitudes of physicians participating in the IN-GHO registry
    F Honecker
    Department of Oncology and Hematology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center, Hamburg, Germany Department of Palliative Care, University Hospital, Jena, Germany Janssen Cilag GmbH, Neuss, Germany University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 29:e19607. 2011
    ..Part of the registry is a geriatric assessment (GA). While there is a widespread notion that GA is helpful in geriatric oncology, little is known about physicians' (ps) perception of GA in oncology practice...
  56. ncbi request reprint Relationship of T lymphocytes, T regulatory cells, and B lymphocytes to clinical outcome in prostate cancer
    M Trepel
    University Medical Center Hamburg Eppendorf, Hubertus Wald Cancer Center, Hamburg, Germany University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 29:4632. 2011
    ..In prostate cancer, systematic profiling of the number and subtype of lymphatic cells in the tumor tissue based on large patient cohorts are lacking...
  57. pmc First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial
    C Bokemeyer
    Tuebingen University Medical Center II, Department of Hematology, Oncology, Rheumatology and Immunology, Eberhard Karls University, Otfried Mueller Str 10, 70276 Tuebingen, Germany
    Br J Cancer 89:29-35. 2003
    ..Compared to data of an international database analysis including 253 patients with mediastinal nonseminoma treated with conventional chemotherapy, the results may indicate that HD-VIP results in an approximately 15% survival improvement...
  58. ncbi request reprint Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors
    F Mayer
    Department of Oncology, Hematology, Immunology and Rheumatology, University of Tübingen Medical Center, Tubingen, Germany
    Ann Oncol 14:825-32. 2003
    ..Even though no uniform pattern of relevant resistance factors has been identified in patients suffering from refractory disease, a significant number of these cases may be caused by defects in the DNA mismatch repair pathway...
  59. ncbi request reprint [Compression syndromes]
    J Wierecky
    Abteilung für Hämatologie, Onkologie, Immunologie und Rheumatologie, Medizinische Klinik II, Universitatsklinikum Tubingen
    Internist (Berl) 46:9-18. 2005
    ..MRI should be preferred in the diagnostic work-up, corticosteroids be administered promptly after biopsy. Radiation therapy or surgical treatment should be started as soon as possible...
  60. ncbi request reprint Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastroint
    C H Kohne
    Department og Internal Medicine I, University of Dresden, Dresden, Germany
    J Clin Oncol 21:3721-8. 2003
    ..This trial was conducted to determine whether high-dose fluorouracil (FU) given as a weekly 24-hour infusion is more active than bolus FU + leucovorin (LV), and whether high-dose infusional FU can be modulated by LV...
  61. ncbi request reprint EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
    C Bokemeyer
    Universitaetsklinikum Tuebingen, Medizinische Klinik Abteilung II, Otfried Mueller St 10, D 72076 Tuebingen, Germany
    Eur J Cancer 40:2201-16. 2004
    ..Additional trials are warranted, especially on the issues of iron replacement and cost-effectiveness of erythropoietic protein therapy, as well as on tumour response/progression and survival...
  62. ncbi request reprint Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 25:32-9. 2002
    ....
  63. ncbi request reprint [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma]
    G Bartsch
    Abteilung für Urologie und Kinderurologie, Urologische Universitätsklinik und Poliklinik Ulm, Prittwitzstrasse 43, 89075 Ulm
    Urologe A 46:1289-90. 2007
  64. ncbi request reprint Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Ann Oncol 13:1017-28. 2002
    ..This investigation evaluates prognostic variables in patients with seminomatous and non-seminomatous extragonadal germ-cell tumors (EGCT) in order to identify relevant factors for long-term outcome following cisplatin-based chemotherapy...
  65. ncbi request reprint Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    J Clin Oncol 19:1641-8. 2001
    ....
  66. ncbi request reprint Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome
    C Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    Cancer 91:1394-401. 2001
    ..Primary radiotherapy seems to be associated with a significantly higher rate of disease recurrence, although most patients will be salvaged by subsequent chemotherapy...
  67. ncbi request reprint Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Anticancer Res 23:1899-901. 2003
    ..The number of cytostatic agents effective in patients with advanced soft tissue sarcoma is limited. Trofosfamide, an alkylating agent, has been shown to be effective in several solid and haematological tumors...
  68. ncbi request reprint Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy
    C Kollmannsberger
    Department of Medicine II, University of Tuebingen, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany
    World J Urol 19:120-5. 2001
    ..It is hoped that the increase in knowledge of the molecular mechanism of testicular cancer may lead to the development of new therapeutic options...
  69. pmc Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer
    C Bokemeyer
    Department of Haematology Oncology, University of Tuebingen Medical Centre, Otfried Muller Strasse 10, 72076 Tuebingen, Germany
    Br J Cancer 87:1066-71. 2002
    ..Despite the frequent use of red blood cell transfusions, median haemoglobin nadirs remained about 7.5-8 g dl(-1) during therapy. A correlation of haemoglobin-values after completion of therapy to overall treatment outcome was found...
  70. ncbi request reprint [Allogeneic hematopoetic cell transplantation in patients with solid tumors - Contra]
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Immunologie und Rheumatologie, Universitatsklinikum Tubingen
    Dtsch Med Wochenschr 127:2215. 2002
  71. pmc Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Haematology Oncology, University of Tuebingen Medical Center, Germany
    Br J Cancer 87:729-32. 2002
    ..Irinotecan at a dose of 300-350 mg m(-2) every 3 weeks appears to have no antitumour activity in patients with cisplatin-refractory germ cell cancer and, thus, further investigation in this disease is not justified...
  72. ncbi request reprint [Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?]
    F Honecker
    Abteilunh Hämatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Tubingen
    Onkologie 24:87-94. 2001
    ..Further clinical trials of chemotherapy in elderly patients with colorectal cancer are necessary to gain information about treatment recommendations...
  73. ncbi request reprint Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer
    C Kollmannsberger
    Department of Internal Medicine, University of Tuebingen Medical Center, Tuebingen, Germany
    Cancer 95:301-8. 2002
    ....
  74. ncbi request reprint A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors
    F Mayer
    Abteilung für Onkologie, Hämatologie, Immunologie und Rheumatologie, Universitatsklinikum Tubingen, Germany
    Ann Oncol 13:755-9. 2002
    ..A phase I study was performed to determine the maximum tolerated dose of the combination of UFT and paclitaxel in patients with advanced solid tumors...
  75. ncbi request reprint Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer S
    H J Schmoll
    Department of Hematology Oncology, University of Halle, Halle, Germany
    J Clin Oncol 21:4083-91. 2003
    ..This analysis reports toxicity and long-term results of a large phase I/II study of sequential high-dose etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced germ cell tumors...
  76. ncbi request reprint Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer
    F Honecker
    Department of Hematology Oncology, University of Tübingen Medical Center, 72076 Tubingen, Germany
    Anticancer Drugs 13:497-503. 2002
    ..Other organ toxicities apart from a slightly higher incidence of peripheral neuropathy were comparable between the two treatment protocols. Efficacy with a response rate of 50% was well preserved by this weekly regimen...
  77. ncbi request reprint [Therapy of elderly patients with colorectal carcinoma]
    F Honecker
    Abteilung für Hämatologie, Onkologie, Rheumatologie und Immunologie der Medizinischen Universitätsklinik Tübingen
    Wien Med Wochenschr 152:170-6. 2002
    ..It is the aim of this manuscript to summarize the current knowledge about the management of colorectal cancer in elderly patients...
  78. ncbi request reprint Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study
    A Jakob
    Department of Hematology Oncology, University Hospital Tubingen, Otfried Mueller Strasse 10, 72076 Tubingen, Germany
    Anticancer Drugs 13:405-10. 2002
    ..It can be safely used in patients who have been intensively pretreated by myelotoxic chemotherapy or who have even relapsed after high-dose chemotherapy with PBSCT...
  79. ncbi request reprint Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
    J Clin Oncol 20:2031-7. 2002
    ..To investigate the efficacy and toxicity of oxaliplatin, a diaminocyclohaxane platinum derivative with incomplete cross-resistance to cisplatin in patients with relapsed or cisplatin-refractory germ cell cancer...
  80. ncbi request reprint Impact of tumor size on the long-term survival of patients with early stage renal cell cancer
    M Kuczyk
    Department of Urology, Eberhard Karls University, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    World J Urol 23:50-4. 2005
    ..The present study demonstrates the need for multivariate statistical approaches when the latest modification of the TNM classification system is critically evaluated...
  81. doi request reprint Stem cell factor as a novel diagnostic marker for early malignant germ cells
    H Stoop
    Department of Pathology, Erasmus MC Erasmus University Medical Center, Daniel den Hoed Cancer Center, Josephine Nefkens Institute, Rotterdam, The Netherlands
    J Pathol 216:43-54. 2008
    ..SCF immunohistochemistry can be a valuable diagnostic tool, in addition to OCT3/4, to screen for precursor lesions of TGCTs, especially in patients with germ cell maturation delay...
  82. doi request reprint Modern treatment options for elderly patients with multiple myeloma
    Martin Görner
    Klinik für Hämatologie und Onkologie, Städtische Kliniken Bielefeld gGmbH, Bielefeld, Germany
    Onkologie 31:335-42. 2008
    ..In this review, we discuss the data available from clinical trials investigating antineoplastic treatment of elderly multiple myeloma patients...
  83. ncbi request reprint Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer
    O Rick
    Department of Hematology, , Campus Virchow Klinikum, Berlin, Germany
    J Clin Oncol 19:81-8. 2001
    ..Peripheral nervous toxicity in approximately one third of patients is a disadvantage of this salvage strategy...
  84. ncbi request reprint Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine
    U Reichmann
    Department of Radiooncology, University of Tuebingen, Tuebingen, Germany
    Ann Oncol 18:1981-4. 2007
    ..This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients...
  85. ncbi request reprint A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
    J A Ajani
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas, 77030, USA
    Invest New Drugs 24:441-6. 2006
    ..With the primary endpoint of assessing ixabepilone's response rate against metastatic gastric cancer previously treated with a taxane, we performed a multi-center phase II trial...
  86. ncbi request reprint A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen, Germany
    Ann Oncol 17:1007-13. 2006
    ..Paclitaxel and EGFR inhibitors have additive antitumour effects in vitro. This phase I study assessed the tolerability, pharmacokinetics and efficacy of the combination of matuzumab and paclitaxel in patients with advanced NSCLC...
  87. ncbi request reprint Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
    C H Kohne
    Department of Internal Medicine, University of Dresden, Dresden
    J Clin Oncol 23:4856-65. 2005
    ..To demonstrate that adding irinotecan to a standard weekly schedule of high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA]) can prolong progression-free survival (PFS)...
  88. ncbi request reprint Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO
    C Kollmannsberger
    Department of Hematology Oncology, Department of Radiation Oncology, University of Tuebingen, Tuebingen
    Ann Oncol 16:1326-33. 2005
    ..The current two studies evaluate the feasibility, toxicity and efficacy of an adjuvant combined modality treatment strategy containing a three to four-drug chemotherapy regimen plus 5-fluorouracil (FU)-based radiochemotherapy...
  89. ncbi request reprint Current aspects of high-dose chemotherapy in germ-cell tumors
    O Rick
    Medizinische Klinik II m S Onkologie Hämatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat, Schumann Str 20 21, 10117 Berlin, Germany
    Crit Rev Oncol Hematol 47:237-48. 2003
    ..Prognostic factors have recently been recognized to aid in this decision...
  90. ncbi request reprint [Chemotherapy for germ cell cancer]
    J Beyer
    Klinik für Hämatologie, Onkologie und Immunologie, Klinikum der Philipps Universität, Marburg
    Urologe A 43:1507-13. 2004
    ..If excessive toxicity is to be avoided and a curative treatment option maintained, overtreatment as well as undertreatment are notorious pitfalls...
  91. ncbi request reprint Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC)
    F Honecker
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 27:583-8. 2004
    ..A review of the most important trials, assessing treatment options in elderly patients with lung cancer, either prospectively or retrospectively, is provided, and still unresolved issues are addressed...
  92. ncbi request reprint Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC)
    F Honecker
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 27:500-5. 2004
    ..Further evaluation of these topics is needed, and can be achieved by trials specifically designed for elderly patients or patients with reduced performance status...
  93. pmc Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Br J Cancer 91:683-7. 2004
    ..In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care...
  94. pmc Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
    R D Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Theodor Kutzer Ufer, D 68167 Mannheim, Germany
    Br J Cancer 91:834-8. 2004
    ..The favourable safety profile and promising activity of the capecitabine/mitomycin C combination, even in heavily pretreated patients, warrant further evaluation in patients with advanced colorectal and gastric cancers...
  95. ncbi request reprint The role of high-dose chemotherapy in relapsed germ cell tumors
    O Rick
    Medizinische Klinik II m S Onkologie Hämatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat, Schumannstrasse 20 21, 10117 Berlin, Germany
    World J Urol 22:25-32. 2004
    ..This report reviews the current treatment strategies and recent developments with respect to HDCT given as salvage treatment and discusses the role of prognostic factors in the management of such situations...
  96. pmc Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
    J T Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tuebingen, Germany
    Br J Cancer 89:2051-6. 2003
    ..In gastric cancer,MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen with promising antitumour activity...
  97. ncbi request reprint Pharmacotherapy of relapsed metastatic testicular cancer
    C Kollmannsberger
    British Columbia Cancer Agency University of British Columbia Vancouver Cancer Centre, Division of Medical Oncology, 600 West 10th Avenue, Vancouver, BC V5Z4E6, Canada
    Expert Opin Pharmacother 9:2259-72. 2008
    ..Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published...